Swedish Orphan Biovitrum AB/ SE0000872095 /
2024-10-09 2:11:55 PM | Chg. - | Volume | Bid2024-07-17 | Ask2024-08-16 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
300.30SEK | - | 419 Turnover: 125,825.70 |
-Bid Size: - | -Ask Size: - | 104.96 bill.SEK | - | 39.65 |
GlobeNewswire
08-08
Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
07-30
ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
GlobeNewswire
05-24
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Act...
GlobeNewswire
05-15
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at ...
GlobeNewswire
05-09
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
GlobeNewswire
05-06
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
05-06
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLON...
GlobeNewswire
05-01
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on...
GlobeNewswire
04-04
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination wit...
GlobeNewswire
04-03
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
GlobeNewswire
03-13
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business U...
GlobeNewswire
03-06
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
GlobeNewswire
03-06
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March...